DDInter849 DDInter1376
Guselkumab is a human immunoglobulin G1 lambda (IgG1λ) monoclonal antibody that selectively blocks interleukin-23. IL-23 is an inflammatory cytokine that activates the CD4+ T-helper (Th17) cell pathway to mediate the inflammatory cascade that induces psoriatic plaque formation. In clinical trials, guselkumab demonstrated improved skin clearance and symptomatic improvements in dermatological manifestations of psoriasis. Developed by Janssen, the subcutenous injection form of guselkumab was approved in July 2017 under the market name Tremfya for the treatment of adult patients with moderate-to-severe plaque psoriasis.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Guselkumab {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zinc gluconate
Guselkumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rivaroxaban
Guselkumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Diroximel fumarate
Guselkumab {u} may lead to a major life threatening interaction when taken with {v} Certolizumab pegol
Guselkumab {u} may lead to a major life threatening interaction when taken with {v} Upadacitinib
Guselkumab may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate
Guselkumab may cause a moderate interaction that could exacerbate diseases when taken with Rivaroxaban
Guselkumab may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Guselkumab may lead to a major life threatening interaction when taken with Certolizumab pegol
Guselkumab may lead to a major life threatening interaction when taken with Upadacitinib